<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To summarize and evaluate the available literature assessing the efficacy and safety of exenatide once weekly for the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>DATA SOURCES: PubMed (1966-January 2012) and International Pharmaceutical Abstracts (1969-January 2012) were searched using the term exenatide once weekly </plain></SENT>
<SENT sid="2" pm="."><plain>Abstracts presented at the European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> Annual Meeting in 2011 and reference citations from publications were reviewed for inclusion </plain></SENT>
<SENT sid="3" pm="."><plain>Eli Lilly and Company and Amylin Pharmaceuticals were contacted for additional unpublished information </plain></SENT>
<SENT sid="4" pm="."><plain>STUDY SELECTION AND DATA EXTRACTION: <z:hpo ids='HP_0000001'>All</z:hpo> English-language articles and abstracts were evaluated for inclusion </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> randomized controlled trials were included in the review </plain></SENT>
<SENT sid="6" pm="."><plain>DATA SYNTHESIS: The efficacy and safety of exenatide once weekly has been evaluated as initial monotherapy and as add-on therapy to <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>, and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> in patients with uncontrolled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for up to 3 years </plain></SENT>
<SENT sid="7" pm="."><plain>Results from 6 randomized, comparator-controlled studies in over 3000 patients indicate that treatment with exenatide once weekly results in significant glycemic improvements and <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Gastrointestinal adverse effects and injection site reactions are common, but rarely lead to drug discontinuation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Exenatide once weekly holds promise as a convenient, efficacious, and well-tolerated antihyperglycemic agent for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Studies evaluating outcomes such as cardiovascular events or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality with exenatide once weekly are lacking </plain></SENT>
</text></document>